25周年を記念 1999-2024
*3年間で¥ 153396、たったの¥ 61358
フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
d AstraZeneca PLC - Pharmaceutical companies based in Rahway, New Jersey and Cambridge, England, respectively - Phase ...
Merck & Co Inc on Thursday reported steady top-line growth, though profit took a hit due to the cost of recent acquis ...
d Daiichi Sankyo Co Ltd - Rahway, New Jersey-based and Tokyo-based pharmaceutical companies - Joint-developed monoclon ...
Merck & Co Inc on Tuesday reported a swing to profit in the second quarter, but lowered its guidance for annual earni ...
Merck & Co Inc on Wednesday said it has agreed to acquire Eyebiotech Ltd for up to USD3 billion, as the company also ...
Merck & Co Inc on Thursday raised its outlook, after posting a strong first quarter. The Rahway, New Jersey-based ph ...
Rahway, New Jersey-based pharmaceutical maker - Announces that the Phase 3 KEYNOTE-A18 trial, showed KEYTRUDA, in comb ...
Merck & Co Inc announced on Tuesday that its cancer treatment Keytruda with chemotherapy has been granted priority re ...
Merck & Co Inc on Thursday said sales jumped in the fourth quarter and in all of 2023 as it eyes future growth Sales ...
LC - London-based venture capital firm investing in "breakthrough" biotechnology companies - Expects USD18.6 million n ...
Merck & Co Inc on Monday said it is diversifying its oncology pipeline as it has entered an agreement to buy Harpoon ...
Astellas Pharma Inc, Merck & Co Inc and Pfizer Inc on Friday announced expanded approval in the US for Keytruda combi ...
Merck & Co Inc on Friday said its drug belzutifan was approved by the US Food & Drug Administration. The news follow ...
Merck & Co Inc on Friday and Monday updated investors on two developments regarding its cancer treatment, Keytruda. ...
Merck & Co on Thursday reported a strong rise in third-quarter revenue and a jump in profit, as it raised its full-ye ...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約